```html

Cryptococcosis – Comprehensive Medical Guide

Overview

Cryptococcosis is a fungal infection caused primarily by the encapsulated yeast Cryptococcus neoformans and, less commonly, Cryptococcus gattii. These organisms are found in soil, decaying wood, pigeon droppings, and certain tree hollows. When inhaled, the fungus can lodge in the lungs and, in susceptible individuals, spread to the central nervous system (CNS) causing meningitis.

Although anyone can be exposed, cryptococcosis most frequently affects people with weakened immune systems, such as those living with HIV/AIDS, organ‑transplant recipients, and patients on long‑term corticosteroids or other immunosuppressive drugs. In immunocompetent hosts, infection is less common but can still occur, especially with the more virulent C. gattii strain.

Globally, an estimated 220,000 new cases of cryptococcal meningitis occur each year, accounting for roughly 15% of AIDS‑related deaths in sub‑Saharan Africa. In the United States, incidence has dropped dramatically with antiretroviral therapy (ART), but >1,000 cases are still reported annually, primarily among HIV‑positive patients.

Symptoms

Symptoms vary according to the site of infection (pulmonary vs. CNS vs. disseminated). Below is a complete list with brief descriptions.

Pulmonary Cryptococcosis

• Persistent cough – dry or mildly productive, lasting weeks.
• Chest pain – pleuritic (sharp pain on breathing) or dull discomfort.
• Shortness of breath – especially on exertion.
• Fever – low‑grade or intermittent.
• Fatigue – generalized weakness.
• Weight loss – often unintentional.

Cryptococcal Meningitis (CNS involvement)

• Headache – usually progressive, severe, and worse at night.
• Neck stiffness (nuchal rigidity).
• Photophobia – sensitivity to light.
• Altered mental status – confusion, decreased concentration, or lethargy.
• Focal neurological deficits – weakness, speech changes, or visual disturbances.
• Seizures – especially in advanced disease.
• Nausea/vomiting – often from raised intracranial pressure.

Disseminated / Skin / Other Sites

• Skin lesions – painless papules, nodules, or ulcerated plaques, sometimes resembling acne.
• Bone pain – if the fungus spreads to the skeleton.
• Eye involvement – uveitis or chorioretinitis causing vision changes.

Causes and Risk Factors

What Causes Cryptococcosis?

The infection begins when airborne yeast cells or spores are inhaled. In most healthy individuals, the immune system clears the organism without illness. In people with impaired immunity, the fungus can multiply in the lungs and disseminate via the bloodstream to the CNS, skin, or other organs.

Key Risk Factors

• HIV/AIDS – especially CD4+ counts < 100 cells/µL (the most important risk factor).
• Organ transplantation – chronic immunosuppressive therapy (e.g., tacrolimus, mycophenolate).
• Long‑term corticosteroid use – doses ≥20 mg prednisone daily for >4 weeks.
• Other immunosuppressive conditions – malignancies, chronic kidney disease, sarcoidosis.
• Exposure to environments rich in bird droppings – pigeon roosts, farms, construction sites.
• Geographic location – higher prevalence in sub‑Saharan Africa, Southeast Asia, and the Pacific Northwest of the U.S. (where C. gattii is endemic).
• Age – infants and elderly have relatively weaker immune responses.

Diagnosis

Prompt diagnosis is crucial because CNS disease can be rapidly fatal. Diagnosis typically involves a combination of clinical suspicion, imaging, and laboratory testing.

Laboratory Tests

• Cryptococcal Antigen (CrAg) Assay – Detects polysaccharide antigen in serum, plasma, or cerebrospinal fluid (CSF). Lateral flow assay (LFA) offers >95% sensitivity and can be performed at point‑of‑care.
• CSF Analysis (lumbar puncture) – Opening pressure measurement, cell count, protein, glucose, and CrAg testing. Elevated opening pressure (>20 cm H₂O) is common in meningitis.
• Fungal Culture – Grows the organism from sputum, bronchoalveolar lavage, CSF, or tissue biopsy; definitive but may take 3–7 days.
• India Ink Stain – Direct microscopic visualization of encapsulated yeast in CSF; less sensitive than CrAg but still used in many labs.
• Polymerase Chain Reaction (PCR) – Molecular detection of Cryptococcus DNA; increasingly available in reference labs.

Imaging

• Chest X‑ray or CT – May show nodules, infiltrates, or cavitary lesions in pulmonary disease.
• Brain MRI or CT – Can reveal meningeal enhancement, gelatinous pseudocysts, or cryptococcomas (mass‑like lesions).

Diagnostic Criteria (Simplified)

1. Clinical signs compatible with pulmonary or CNS infection.
2. Positive CrAg in serum or CSF **or** culture/India ink demonstrating *Cryptococcus*.
3. Exclusion of alternative diagnoses (e.g., bacterial meningitis, TB).

Treatment Options

Treatment is divided into three phases: induction, consolidation, and maintenance. Regimens differ slightly for HIV‑positive vs. non‑HIV patients and for CNS versus isolated pulmonary disease.

Induction Therapy (First 2 weeks)

• Amphotericin B deoxycholate 0.7–1 mg/kg IV daily **plus** flucytosine 100 mg/kg/day orally in four divided doses. This combination is the gold standard for cryptococcal meningitis (WHO, CDC).
• For patients who cannot tolerate amphotericin B (e.g., renal dysfunction), the lipid formulations (liposomal amphotericin B 3–5 mg/kg) are alternatives with less nephrotoxicity.

Consolidation Therapy (8 weeks)

• Fluconazole 400–800 mg orally daily.
• Switch to fluconazole after negative CSF cultures and clinically stable intracranial pressure.

Maintenance (Secondary Prophylaxis) – Minimum 12 months

• Fluconazole 200 mg orally daily.
• Patients with HIV should remain on ART and maintain CD4+ counts >200 cells/µL before stopping prophylaxis.

Adjunctive Management

• Therapeutic lumbar puncture – Repeated removal of CSF to control elevated opening pressure; recommended when pressure >25 cm H₂O.
• Management of electrolyte disturbances – Amphotericin B can cause hypokalemia and hypomagnesemia; monitor labs regularly.
• Monitoring for drug toxicity – Liver function tests for fluconazole, renal function for amphotericin B.

Lifestyle & Supportive Measures

• Stay hydrated; avoid nephrotoxic agents (NSAIDs, IV contrast) while on amphotericin.
• Adhere strictly to antiretroviral therapy (if HIV‑positive) to improve immune recovery.
• Maintain a balanced diet rich in protein to support healing.

Living with Cryptococcosis

Even after successful treatment, many patients need ongoing care. Here are practical tips for daily life.

• Medication adherence – Use a pill organizer or set alarms. Missing doses of fluconazole can lead to relapse.
• Regular follow‑up – Blood work every 2–4 weeks initially, then every 3–6 months. Repeat CSF analysis is usually done at 2 weeks and 10 weeks of therapy.
• Monitor for symptoms of increased intracranial pressure – New headaches, vomiting, or vision changes warrant immediate evaluation.
• Vaccinations – Keep immunizations up to date (influenza, pneumococcal, COVID‑19) to reduce secondary infections.
• Nutrition & exercise – Light to moderate activity as tolerated; avoid extreme fatigue.
• Support networks – Join local or online support groups for people living with HIV or organ‑transplant recipients; sharing experiences reduces isolation.

Prevention

Because exposure to *Cryptococcus* is common, prevention focuses on reducing inhalation of large inocula and strengthening host immunity.

Environmental Measures

• Avoid cleaning pigeon droppings or contaminated soil without protective masks.
• Use N95 respirators when working in high‑risk settings (e.g., demolition, bird‑cage cleaning).
• Keep indoor spaces well‑ventilated and avoid accumulation of bird nests.

Medical Preventive Strategies

• Screening for CrAg in HIV‑positive patients with CD4+ < 100 cells/µL. Pre‑emptive fluconazole therapy reduces meningitis incidence by up to 80% (WHO, 2022).
• Early initiation of effective antiretroviral therapy (ART) in HIV; keep CD4+ counts >200 cells/µL.
• For transplant recipients, maintain target immunosuppressive levels and consider antifungal prophylaxis during high‑risk periods (first 6 months post‑transplant).

Complications

If left untreated or inadequately treated, cryptococcosis can lead to serious, sometimes fatal, complications.

• Cryptococcal meningitis – leading cause of death in AIDS patients in sub‑Saharan Africa.
• Increased intracranial pressure – may cause vision loss, brain herniation.
• Cryptococcomas – mass lesions that can mimic tumors, requiring neurosurgical intervention.
• Disseminated disease – involvement of skin, bone, or bloodstream causing sepsis.
• Drug toxicities – amphotericin‑induced renal failure, fluconazole‑related liver injury.
• Immune reconstitution inflammatory syndrome (IRIS) – paradoxical worsening after ART initiation; requires careful balancing of antifungal and anti‑inflammatory therapy.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, National Institute of Allergy and Infectious Diseases (NIAID), Cleveland Clinic, *Lancet Infectious Diseases* (2023), *Clinical Infectious Diseases* (2022).

```